WO2015071861A3 - Fungus mediated stereo-selective bioreduction of keto intermediates of pharmaceutically active compounds to their corresponding hydroxy compounds - Google Patents

Fungus mediated stereo-selective bioreduction of keto intermediates of pharmaceutically active compounds to their corresponding hydroxy compounds Download PDF

Info

Publication number
WO2015071861A3
WO2015071861A3 PCT/IB2014/066031 IB2014066031W WO2015071861A3 WO 2015071861 A3 WO2015071861 A3 WO 2015071861A3 IB 2014066031 W IB2014066031 W IB 2014066031W WO 2015071861 A3 WO2015071861 A3 WO 2015071861A3
Authority
WO
WIPO (PCT)
Prior art keywords
bioreduction
selective
stereo
pharmaceutically active
fungus
Prior art date
Application number
PCT/IB2014/066031
Other languages
French (fr)
Other versions
WO2015071861A2 (en
Inventor
Sawraj SINGH
Saravanan JOTHI
Sanjay DESPANDE
Sheetal LAL
Shrivallabh Desai
Original Assignee
Biocon Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biocon Limited filed Critical Biocon Limited
Publication of WO2015071861A2 publication Critical patent/WO2015071861A2/en
Publication of WO2015071861A3 publication Critical patent/WO2015071861A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/10—Nitrogen as only ring hetero atom
    • C12P17/12—Nitrogen as only ring hetero atom containing a six-membered hetero ring
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/18—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing at least two hetero rings condensed among themselves or condensed with a common carbocyclic ring system, e.g. rifamycin

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

The current disclosure discloses stereo-selective bioreduction of keto intermediates of various pharmaceutically active compounds to their corresponding hydroxyl compounds by microbes.
PCT/IB2014/066031 2013-11-14 2014-11-14 Fungus mediated stereo-selective bioreduction of keto intermediates of pharmaceutically active compounds to their corresponding hydroxy compounds WO2015071861A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN5255CH2013 2013-11-14
IN5255/CHE/2013 2013-11-14

Publications (2)

Publication Number Publication Date
WO2015071861A2 WO2015071861A2 (en) 2015-05-21
WO2015071861A3 true WO2015071861A3 (en) 2015-09-17

Family

ID=53058216

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2014/066031 WO2015071861A2 (en) 2013-11-14 2014-11-14 Fungus mediated stereo-selective bioreduction of keto intermediates of pharmaceutically active compounds to their corresponding hydroxy compounds

Country Status (1)

Country Link
WO (1) WO2015071861A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104893989B (en) * 2015-05-29 2018-01-12 浙江工业大学 Rhizopus microsporus must shape mutation ZJPH1308 and the application in sitagliptin intermediate is prepared
CN105274027B (en) * 2015-11-05 2018-06-05 重庆邮电大学 Pseudomonas pseudoalcaligenes strain and its application in sitagliptin intermediate is prepared
CN107382875B (en) * 2017-06-26 2020-06-19 浙江美诺华药物化学有限公司 Synthetic method of rosuvastatin calcium chiral isomer impurity
CN107827812B (en) * 2017-11-23 2021-06-08 中山奕安泰医药科技有限公司 Chiral synthesis method of bepotastine besilate intermediate
CN109957584A (en) * 2017-12-25 2019-07-02 尚科生物医药（上海）有限公司 One kind being used to prepare the Biocatalysis method of (R)-(4- chlorphenyl) -2- pyridinemethanol
WO2024049229A1 (en) * 2022-08-31 2024-03-07 동국대학교 산학협력단 Cosmetic composition for preventing or ameliorating skin diseases, comprising morus alba-derived compound as active ingredient

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5686298A (en) * 1992-11-12 1997-11-11 E. R. Squibb & Sons, Inc. Enzymatic reduction method for the preparation of compounds useful for preparing taxanes
EP0997535A2 (en) * 1998-10-29 2000-05-03 Pfizer Products Inc. Stereoselective microbial reduction of a racemic tetralone
US7148055B2 (en) * 2001-10-05 2006-12-12 Kaneka Corporation Process for production of optically active 3-hydroxypentanenitrile

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5686298A (en) * 1992-11-12 1997-11-11 E. R. Squibb & Sons, Inc. Enzymatic reduction method for the preparation of compounds useful for preparing taxanes
EP0997535A2 (en) * 1998-10-29 2000-05-03 Pfizer Products Inc. Stereoselective microbial reduction of a racemic tetralone
US7148055B2 (en) * 2001-10-05 2006-12-12 Kaneka Corporation Process for production of optically active 3-hydroxypentanenitrile

Also Published As

Publication number Publication date
WO2015071861A2 (en) 2015-05-21

Similar Documents

Publication Publication Date Title
WO2015071861A3 (en) Fungus mediated stereo-selective bioreduction of keto intermediates of pharmaceutically active compounds to their corresponding hydroxy compounds
EP3023098A4 (en) Self-emulsifying composition of -3 fatty acid
EP3023099A4 (en) Self-emulsifying composition of -3 fatty acid
EP2986681A4 (en) An aqueous coating composition
WO2016098131A3 (en) Improved method for the synthesis of ferric oraganic compounds
EP3087184A4 (en) Methods and compositions for the specific inhibition of glycolate oxidase (hao1) by double-stranded rna
IN2012MU03723A (en)
EP3052635A4 (en) Alcohol dehydrogenase variants
EP3538219A4 (en) Topical compositions for the treatment of acne
EP3022204B8 (en) Novel process for the preparation of spiroheterocyclic pyrrolidine diones
WO2015092810A3 (en) Amorphous form of idelalisib
EP3082421A4 (en) Low voc gibberellin formulations
EP3229814A4 (en) Co-crystal of dapagliflozin with citric acid
WO2015037016A3 (en) An improved process for the preparation of ticagrelor and intermediates thereof
HK1217495A1 (en) Therapeutically active 17-nitrogen substituted estratrienthiazole derivatives as inhibitors of 17.beta.-hydroxysteroid dehydrogenase 17- 17-
WO2017064627A3 (en) Process for preparation of eribulin and intermediates thereof
EP3320162A4 (en) Assembly for adjustable attachment of pole, beam or similar to a fundament
WO2014080012A8 (en) Connection pole for an accumulator, pole shaft of an accumulator, and accumulator
WO2014195861A3 (en) Preparation of ticagrelor
EP3405429A4 (en) Formation of functionalized nanoparticles by supramolecular co-assembly
WO2011088020A9 (en) Modified saponins for the treatment of fungal infections
WO2015097717A3 (en) AN IMPROVED PROCESS FOR THE PREPARATION OF β-CAROTENE
EP3060546A4 (en) Processes for the preparation of unsaturated esters
EP3499745A4 (en) Tower mounted amplifier
EP3475299A4 (en) Compounds useful to treat metabolic disorders

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 14862142

Country of ref document: EP

Kind code of ref document: A2